Jun Long, Yian Wang, Xianjie Jiang, Junshang Ge, Mingfen Chen, Boshu Zheng, Rong Wang, Meifeng Wang, Meifang Xu, Qi Ke, Jie Wang
T cell engineering, particularly via chimeric antigen receptor (CAR) modifications for enhancing tumor specificity, has shown efficacy in treating hematologic malignancies. The extension of CAR-T cell therapy to solid tumors, however, is impeded by several challenges: the absence of tumor-specific antigens, antigen heterogeneity, a complex immunosuppressive tumor microenvironment, and physical barriers to cell infiltration. Additionally, limitations in CAR-T cell manufacturing capacity and the high costs associated with these therapies restrict their widespread application...
March 14, 2024: Advanced Healthcare Materials